Cargando…
Data driven polypharmacological drug design for lung cancer: analyses for targeting ALK, MET, and EGFR
Drug design of protein kinase inhibitors is now greatly enabled by thousands of publicly available X-ray structures, extensive ligand binding data, and optimized scaffolds coming off patent. The extensive data begin to enable design against a spectrum of targets (polypharmacology); however, the data...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer International Publishing
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5496928/ https://www.ncbi.nlm.nih.gov/pubmed/29086093 http://dx.doi.org/10.1186/s13321-017-0229-8 |